Savara (SVRA) Competitors $3.20 -0.02 (-0.62%) (As of 10:20 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SVRA vs. GERN, NAMS, IDYA, CNTA, WVE, MIRM, AKRO, SUPN, AMPH, and IRONShould you be buying Savara stock or one of its competitors? The main competitors of Savara include Geron (GERN), NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), Centessa Pharmaceuticals (CNTA), Wave Life Sciences (WVE), Mirum Pharmaceuticals (MIRM), Akero Therapeutics (AKRO), Supernus Pharmaceuticals (SUPN), Amphastar Pharmaceuticals (AMPH), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical preparations" industry. Savara vs. Geron NewAmsterdam Pharma IDEAYA Biosciences Centessa Pharmaceuticals Wave Life Sciences Mirum Pharmaceuticals Akero Therapeutics Supernus Pharmaceuticals Amphastar Pharmaceuticals Disc Medicine Geron (NASDAQ:GERN) and Savara (NASDAQ:SVRA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, community ranking, analyst recommendations and institutional ownership. Is GERN or SVRA more profitable? Savara has a net margin of 0.00% compared to Geron's net margin of -682.48%. Savara's return on equity of -58.89% beat Geron's return on equity.Company Net Margins Return on Equity Return on Assets Geron-682.48% -67.53% -45.46% Savara N/A -58.89%-46.44% Does the media refer more to GERN or SVRA? In the previous week, Geron had 15 more articles in the media than Savara. MarketBeat recorded 22 mentions for Geron and 7 mentions for Savara. Geron's average media sentiment score of 0.86 beat Savara's score of 0.68 indicating that Geron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 9 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer GERN or SVRA? Geron received 195 more outperform votes than Savara when rated by MarketBeat users. Likewise, 70.03% of users gave Geron an outperform vote while only 66.67% of users gave Savara an outperform vote. CompanyUnderperformOutperformGeronOutperform Votes49370.03% Underperform Votes21129.97% SavaraOutperform Votes29866.67% Underperform Votes14933.33% Which has preferable valuation & earnings, GERN or SVRA? Savara has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeron$29.48M81.20-$184.13M-$0.32-12.38SavaraN/AN/A-$54.70M-$0.43-7.47 Do analysts prefer GERN or SVRA? Geron currently has a consensus price target of $7.15, indicating a potential upside of 80.56%. Savara has a consensus price target of $10.17, indicating a potential upside of 216.72%. Given Savara's higher probable upside, analysts plainly believe Savara is more favorable than Geron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Geron 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.09Savara 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has more risk & volatility, GERN or SVRA? Geron has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Savara has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Do insiders & institutionals believe in GERN or SVRA? 73.7% of Geron shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 3.1% of Geron shares are owned by company insiders. Comparatively, 5.1% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryGeron beats Savara on 10 of the 18 factors compared between the two stocks. Ad The Oxford Club2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies Set to See Enormous Profit Potential.Details Here. Get Savara News Delivered to You Automatically Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVRA vs. The Competition Export to ExcelMetricSavaraPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$550.90M$6.85B$5.15B$9.28BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-7.4710.79135.4217.51Price / SalesN/A286.571,184.62142.21Price / CashN/A56.6540.4237.95Price / Book3.095.404.894.94Net Income-$54.70M$152.04M$118.71M$225.59M7 Day Performance-8.02%-4.19%15.74%-1.07%1 Month Performance8.45%2.70%15.70%7.23%1 Year Performance-30.22%17.16%34.85%22.97% Savara Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVRASavara3.3498 of 5 stars$3.20-0.6%$10.17+217.7%-28.4%$549.18MN/A-7.44N/AInsider TradeGap UpGERNGeron4.0043 of 5 stars$3.78-2.1%$7.15+89.2%+74.7%$2.29B$29.48M-12.06141Short Interest ↓NAMSNewAmsterdam Pharma2.5673 of 5 stars$24.50-0.8%$36.20+47.8%+147.8%$2.26B$33.59M0.0057Insider TradeIDYAIDEAYA Biosciences4.3739 of 5 stars$25.95+3.0%$53.67+106.8%-24.9%$2.24B$3.92M-10.8180Analyst ForecastShort Interest ↓CNTACentessa Pharmaceuticals3.331 of 5 stars$16.38-1.1%$25.83+57.7%+147.5%$2.16B$6.85M-10.8372Insider TradeNews CoverageWVEWave Life Sciences4.916 of 5 stars$13.54+0.7%$22.22+64.1%+227.7%$2.07B$113.31M-12.11240Positive NewsMIRMMirum Pharmaceuticals4.2538 of 5 stars$42.32-0.3%$57.73+36.4%+22.1%$2.03B$307.03M-21.01140News CoverageAKROAkero Therapeutics3.9591 of 5 stars$29.04+0.5%$46.83+61.3%+33.6%$2.03BN/A-7.7030Short Interest ↓SUPNSupernus Pharmaceuticals2.4962 of 5 stars$36.63+1.3%$36.00-1.7%+32.9%$2.02B$651.97M33.91580AMPHAmphastar Pharmaceuticals4.8584 of 5 stars$40.90-3.2%$60.33+47.5%-27.8%$1.97B$644.40M14.081,761Insider TradeIRONDisc Medicine3.4384 of 5 stars$65.31+0.6%$87.50+34.0%+10.7%$1.94BN/A-16.3078Gap Down Related Companies and Tools Related Companies GERN Alternatives NAMS Alternatives IDYA Alternatives CNTA Alternatives WVE Alternatives MIRM Alternatives AKRO Alternatives SUPN Alternatives AMPH Alternatives IRON Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SVRA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Savara With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
